Molecular genetics of the Bare lymphocyte syndrome

Reviews in Immunogenetics

Volumn 2, Issue 2, 2000, Pages 267-282

  Masternak, K ^a   Muhlethaler Mottet, A ^a   Villard, J ^a   Peretti, M ^a   Reith, W ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Bare lymphocyte syndrome; Class II transactivator (CIITA); MHC class II deficiency; Primary immunodeficiency; Regulatory factor (RFX)

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR;

AUTOSOMAL RECESSIVE DISORDER; BARE LYMPHOCYTE SYNDROME; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE DEFICIENCY; MOLECULAR GENETICS; NONHUMAN; REVIEW;

ANIMAL; DNA-BINDING PROTEINS; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMAN; MICE; MOLECULAR BIOLOGY; SEVERE COMBINED IMMUNODEFICIENCY; TRANSCRIPTION FACTORS;

EID: 0033781550     PISSN: 13981714     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Trends Genet
2. MHC and T cell development
3. Assembly, transport, and function of MHC class II molecules
4. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases
5. Major histocompatibility complex class II deficiency: Clinical manifestations, immunologic features, and outcome
6. Combined immunodeficiency with defective expression in MHC class II genes
7. Regulation of MHC class II genes: Lessons from a disease
8. Major histocompatibility complex class II deficiency: A clinical review
9. Combined immunodeficiency disease associated with absence of cell surface HLA A and B antigen
10. Failure of lymphocyte-membrane HLA A and B expression in two siblings with combined immunodeficiency
11. Impaired cell-to-cell interaction in partial combined immunodeficiency with variable expression of HLA antigens
12. Clinical and immunological studies in a patient with the 'Bare Lymphocyte' syndrome
13. Defective expression of HLA-D-region determinants in children with congenital agammaglobulinemia and malabsorption: A new syndrome
14. Combined immunodeficiency with defective expression of HLA: Modulation of an abnormal HLA synthesis and functional studies
15. Two complementation groups account for most cases of inherited MHC class II deficiency
16. Primary immunodeficiency diseases: Report of a WHO scientific group
17. The bare lymphocyte syndrome
18. A transacting class II regulatory gene unlinked to the MHC controls expression of HLA class II genes
19. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (Bare Lymphocyte Syndrome)
20. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency
21. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency
22. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
23. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II
24. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X
25. Regulation of major histocompatibility complex class II genes: X, Y and other letters of the alphabet
26. Sequences and factors: A guide to MHC class-II transcription
27. Regulation of MHC gene expression
28. Regulation of transcription of MHC class II genes
29. Developing and shedding inhibitions: How MHC class II molecules reach maturity
30. Invariant chain structure and MHC class II function
31. Analysis of transcripts of genes located within the HLA-D region in B-cells from an HLA-severe combined immunodeficiency individual
32. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes
33. Normal T cell receptor V beta usage in a primary immunodeficiency associated with HLA class II deficiency
34. Human T cell repertoire generation in the absence of MHC class II expression results in a circulating CD4+CD8 - Population with altered physicochemical properties of complementarity-determining region 3
35. Molecular Basis of Major Histocompatibility Class II Deficiency
36. Bone marrow transplantation in major histocompatibility complex class II deficiency: A single-center study of 19 patients
37. Protease treatment of nuclear extracts distinguishes between class II MHC X1 box DNA-binding proteins in wild-type and class II-deficient B cells
38. Class II MHC transcriptional mutants are defective in higher order complex formation
39. Congenital immunodeficiencies associated with absence of HLA class II antigens on lymphocytes result from distinct mutations in trans-acting factors
40. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis
41. Genetic complexity of regulatory mutants defective for HLA class-II gene expression
42. Human B cell variants immunoselected against a single Ia antigen subset have lost expression in several Ia antigen subsets
43. Stable variants affecting B cell alloantigens in human lymphoid cells
44. aIr-1, a newly found locus on mouse chromosome 16 encoding a transacting activator factor for MHC class II gene expression
45. Human chromosome 16 encodes a factor involved in induction of class II major histocompatibility antigens by interferon gamma
46. Class II transactivator regulates the expression of multiple genes involved in antigen presentation
47. Two novel mutations in the MHC class II transactivator CIITA in a second patients from MHC class II deficiency complementation group A
48. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene
49. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA
50. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5
51. Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis
52. The bare lymphocyte syndrome: Molecular clues to the transcriptional regulation of major histocompatibility complex class II genes
53. RFX proteins, a novel family of DNA binding proteins conserved in the eukaryotic kingdom
54. Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class II deficiency
55. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene
56. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5
57. Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: Identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor
58. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency
59. Genetic and molecular definition of complementation group D in MHC class II deficiency
60. Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function
61. Structural constraints within a trimeric transcriptional regulatory region: Constitutive and Interferon-g inducible expression of the HLA-DRA gene
62. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y
63. The DMB promoter: Delineation, in vivo footprint, trans-activation, and trans-dominant suppression
64. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region
65. Sequences homologous to class II MHC W, X, and Y elements mediate constitutive and IFN-gamma-induced expression of human class II-associated invariant chain gene
66. Human major histocompatibility complex class II-associated invariant chain gene promoter. Functional analysis and in vivo protein/DNA interactions of constitutive and IFN-gamma-induced expression
67. Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex
68. The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters
69. Functional complementation of MHC class II regulatory mutants by the purified X box binding protein RFX
70. A functionally essential domain of RFX5 mediates activation of MHC class II promoters by promoting cooperative binding between RFX and NF-Y
71. Orientation and positional mapping of the subunits of the multicomponent transcription factors RFX and X2BP to the major histocompatibility complex class II transcriptional enhancer
72. Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding
73. In vivo footprinting of MHC class II genes: Bare promoters in the bare lymphocyte syndrome
74. Three in vivo promoter phenotypes in MHC class II deficient combined immunodeficiency
75. Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene
76. Cooperative binding between factors RFX and X2bp to the X and X2 boxes of MHC class II promoters
77. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes
78. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex
79. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors
80. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy
81. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element
82. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: Generation of transdominant-negative mutants
83. Activation of class II MHC genes requires both the X box and the class II transactivator (CIITA)
84. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency
85. The class II trans-activator CIITA interacts with the TBP-associated factor TAF II 32
86. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein
87. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection
88. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator
89. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes
90. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome
91. GTP binding by class II transactivator: Role in nuclear import
92. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA
93. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA
94. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes
95. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1
96. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
97. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta
98. Identification of distinct regions of 5 flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene
99. Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes
100. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene
101. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression
102. Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression
103. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
104. Quantitative control of MHC class II expression by the transactivator CIITA
105. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma
106. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes
107. Isolation of a B-cell-specific promoter for the human class II transactivator
108. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha
109. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression
110. Mice lacking the transcription factor CIITA - A second look
111. Reduced IL-4-,lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain
112. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice
113. The thymus in 'bare lymphocyte' syndrome: Significance of expression of major histocompatibility complex antigens on thymic epithelial cells in intrathymic T-cell maturation
114. Induction of MHC class I expression by the MHC class II transactivator CIITA
115. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: The ISRE-mediated route and a novel pathway involving CIITA
116. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes
117. Shared regulatory elements in the promoters of MHC class I and class II genes
118. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production
119. Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D a and b chains
120. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients
121. Twin boys with major histocompatibility complex class II deficiency but inducible immune responses
122. Prenatal diagnosis of severe combined immunodeficiency with defective synthesis of HLA molecules
123. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B